Skip to main navigation
Skip to search
Skip to main content
Rutgers, The State University of New Jersey Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Federal Grants
Research output
Search by expertise, name or affiliation
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies
Sanjay Goel
, Minaxi Jhawer
, Lakshmi Rajdev
, Una Hopkins
, Karen Fehn
, Cheryl Baker
, Hoo G. Chun
, Della Makower
, Leon Landau
, Anthony Hoffman
, Scott Wadler
, Sridhar Mani
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Phase I Clinical Trial
100%
Gastrointestinal
100%
Irinotecan
100%
Solid Malignancies
100%
Capecitabine
100%
Neutropenia
42%
Hand-foot Syndrome
28%
Dose-limiting Toxicity
28%
Maximum Tolerated
28%
Colon Cancer
14%
Advanced Solid Tumors
14%
Anorexia
14%
One Dose
14%
Dose Escalation
14%
Anti-tumor Response
14%
5-fluorouracil (5-FU)
14%
Dose Level
14%
Diarrhea
14%
Intravenous Infusion
14%
Toxic Death
14%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Irinotecan
100%
Capecitabine
100%
Neutropenia
42%
Hand Foot Syndrome
28%
Maximum Tolerated Dose
28%
Solid Malignant Neoplasm
14%
Anorexia
14%
Fluorouracil
14%
Diarrhea
14%
Colon Carcinoma
14%